DESTINY-Lung04 reports a first-line result for HER2-mutant lung cancer

DESTINY-Lung04 tested trastuzumab deruxtecan against immunotherapy plus chemotherapy for advanced HER2-mutant non-small-cell lung cancer. The phase 3 result is promising, with safety, publication, and regulatory questions still in view. Evidence checked 3 November 2026.

At a glance

In September 2026, the phase 3 DESTINY-Lung04 trial reported that trastuzumab deruxtecan (T-DXd; Enhertu) improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in previously untreated advanced or metastatic HER2-mutant non-squamous non-small-cell lung cancer (NSCLC). Among 454 participants, median progression-free survival was 14.3 months with T-DXd and 8.3 months with standard therapy; the hazard ratio was 0.63. This was a conference presentation and sponsor report at publication time, so full peer-reviewed details and regulatory review matter.

What is HER2 doing in lung cancer?

HER2 is a protein involved in cell signaling. In some lung cancers, a mutation in the HER2 gene changes the protein’s behavior and drives tumor growth. This is not the same as HER2 overexpression, and a test that identifies a mutation is not interchangeable with a test that measures how much protein is present. The distinction affects which treatment evidence applies.

Trastuzumab deruxtecan is an antibody-drug conjugate. Its antibody binds HER2; attached chemotherapy payload is delivered into cells after the complex is internalized. The approach combines target recognition with a potent cytotoxic drug. “Targeted” does not mean harmless or perfectly selective: payload can affect nearby and healthy cells, and the drug has a clinically important risk of interstitial lung disease/pneumonitis.

What did DESTINY-Lung04 report?

The trial randomized 454 people with unresectable locally advanced or metastatic HER2-mutant non-squamous NSCLC, without prior systemic treatment for advanced disease, to T-DXd or pembrolizumab with platinum-pemetrexed chemotherapy. The primary endpoint was progression-free survival assessed by blinded independent review. Median progression-free survival was 14.3 months versus 8.3 months, corresponding to a 37% lower relative hazard of progression or death (HR 0.63; 95% CI 0.50–0.79). Response and duration-of-response measures were also reported. Grade 3 or higher treatment-related adverse events were reported in about one third of each group, while the types of toxicity differed.

These findings were presented at the 2026 World Conference on Lung Cancer; AstraZeneca’s release includes the top-line numbers. The report is company-authored, and a conference abstract is not a substitute for full trial publication. Readers should look for complete safety tables, subgroup detail, and follow-up as they become available. The trial record is NCT05048797.

How should we interpret progression-free survival?

Progression-free survival measures the time until cancer worsens or a participant dies. It can be meaningful, especially when disease control relieves symptoms or delays the need for another treatment. But it does not, by itself, answer whether people live longer overall or feel better during treatment. The median describes the middle of each group’s observed times; it does not predict an individual’s course.

The trial compared two complete treatment strategies. It did not compare T-DXd with every available drug, nor did it study patients whose tumors merely overexpress HER2 without the relevant mutation. Its result should be applied only to a clinically and molecularly similar population after specialist review.

What is the safety trade-off?

T-DXd can cause pneumonitis, an inflammation of lung tissue that can become severe or fatal. In a lung cancer population, new breathlessness or cough can have several causes, which makes timely assessment essential. This is not a reason to dismiss the drug; it is a reason to pair a promising result with monitoring and prompt clinical evaluation. The trial’s complete safety analysis should guide practice, not a headline efficacy number alone.

Why does this matter for African oncology?

Precision oncology depends on reliable molecular testing. Access to sequencing and pathology varies widely across African countries, as do drug registration, reimbursement, and specialist monitoring. The biology is not geographically confined, but trial representation and local implementation determine how directly a result travels. Regional cancer centers could help by linking molecular testing to treatment pathways and collecting outcomes, while health systems assess cost and safety capacity. This trial has not established population-specific effectiveness or access in Africa.

What comes next?

Regulatory authorities will evaluate the full dataset and each jurisdiction will make its own decision. Peer-reviewed publication and longer follow-up should clarify overall survival, patient-reported outcomes, rare harms, and how this regimen fits beside other molecularly guided therapies. The study marks progress in a mutation-defined group; it does not make all lung cancers alike.

Questions readers ask

Is Enhertu now approved as first-line lung cancer treatment worldwide?

No. A positive trial and conference presentation are not universal regulatory approval. Check local regulator notices and guidelines.

Does a HER2-positive result guarantee eligibility?

Not necessarily. DESTINY-Lung04 focused on HER2 mutations in a defined NSCLC population. A clinician must interpret the exact assay and tumor context.

Is it safer because it is targeted?

Targeting can improve delivery to cancer cells but does not remove serious risks, including lung inflammation.

Sources

• DESTINY-Lung04 results, AstraZeneca/Daiichi Sankyo (14 Sept 2026)
• DESTINY-Lung04 registry, ClinicalTrials.gov

Continue exploring

A new immune partner for stage III colon cancer. The pancreatic cancer pill that finally corners a slippery target.

Cover: Illustrative lung histopathology by Mikael Häggström, M.D., CC0 1.0. This is a different lung cancer subtype and is not from the HER2-mutant DESTINY-Lung04 trial. Credit: Mikael Häggström, M.D.. CC0 1.0. Original source.